Comments 1 - 9 of 9 Search these comments
I’d rather use ivermectin.
But the more options that come out for treatment the better. At some point, the media won’t be able to demonize ALL of them! So many vaccinated sheeple are being infected with Covid and suffering through sickness that (some of them) they’re getting red pilled. They’re like “I did everything, followed all the rules, masked and socially distanced for months, then took a vax with bad side effects because it was “good for the country” and would make me immune! Now I’m sick with Covid.”
And then they’re looking for another treatment and everything has been cancelled by the media. HCQ is “Trump pills,” Ivermectin is “horse dewormer,” and herbal remedies are for “flat earthers.”
Now even this Merck pill is being demonized, least someone out there who is vax hesitant decides to forego it forever in favor of treatment options like this one.
Molnupiravir ugh
Alex Berenson 9 hr ago
402
Yes, molnupiravir - a pill to treat Covid - seems to reduce hospitalizations and deaths, assuming Merck’s press release from last week holds up.
But it is yet another story of the US health care system and drug development gone awry.
A Miami hedge-fund manager and his wife - Wayne and Wendy Holman - are likely to make hundreds of millions of dollars, possibly billions, on it - and they took almost no risk. They basically got in the way of Merck licensing it from Emory University, where taxpayers had paid for its early development (this is how we make drugs in the United States, friends).
Added bonus: almost 20 years ago, Wendy Holman, who at the time had a different husband and a different last name, saw her name pop up in the same insider trading scandal that ensnared Martha Stewart. It too involved a drug company.
Robert W Malone, MD
@RWMaloneMD
2hNYT: "Merck Will Share Formula for its Covid Pill With Poor Countries"
The company announced a licensing deal that will allow the drug, molnupiravir, to be made and sold cheaply in 105 developing nations.
nytimes.com/2021/10/27/healt…
Merck Will Share Formula for its Covid Pill With Poor Countries
The company announced a licensing deal that will allow the drug, molnupiravir, to be made and sold cheaply in 105 developing nations.
Robert W Malone, MD
@RWMaloneMD
2h
How kind of them. Now that trials in India have demonstrated how toxic it is. And by the way, US Taxpayers funded development of this. Merck is such a kind and considerate pharmaceutical company. They only care about world health, not profit.
2:21 PM · Oct 27, 2021
NY Times Casually Admits New FDA-Approved Merck COVID Drug Might Actually Mutate Healthy Human DNA by Accident and Impact Male Fertility
By Jim Hoft
Published December 14, 2021 at 11:23am
Antiviral treatments lead to the rapid accrual of hundreds of SARS-CoV-2 mutations in immunocompromised patients
The antiviral Molnupiravir (Lageviro) is widely used across the world to treat SARS-CoV-2 infection. Molnupiravir reduces viral replication by inducing mutations throughout the genome, yet in patients that do not clear the infection, the longer-term impact of the drug on virus evolution is unclear. Here, we used a case-control approach to monitor SARS-CoV-2 genomes through time in nine immunocompromised -patients with five treated with Molnupiravir. Within days of treatment, we detected a large number of low-frequency mutations in patients and that these new mutations could persist and, in some cases, were fixed in the virus population. All patients treated with the drug accrued new mutations in the spike protein of the virus, including non-synonymous mutations that altered the amino acid sequence. Our study demonstrates that this commonly used antiviral can supercharge viral evolution in immunocompromised patients, potentially generating new variants and prolonging the pandemic.
molnupiravir
However, it is possible that some patients treated with molnupiravir might not fully clear SARS-CoV-2 infections, with the potential for onward transmission of molnupiravir-mutated viruses. We set out to systematically investigate global sequencing databases for a signature of molnupiravir mutagenesis. We find that a specific class of long phylogenetic branches appear almost exclusively in sequences from 2022, after the introduction of molnupiravir treatment, and in countries and age-groups with widespread usage of the drug. We calculate a mutational spectrum from the AGILE placebo-controlled clinical trial of molnupiravir and show that its signature, with elevated G-to-A and C-to-T rates, largely corresponds to the mutational spectrum seen in these long branches. Our data suggest a signature of molnupiravir mutagenesis can be seen in global sequencing databases, in some cases with onwards transmission.
You can have h0mo sex though.